Brief: Ipsen Provides Update On Contact-02 Phase III Trial

Ipsen SA

15/09/2024 13:55

Sept 15 (Reuters) - Ipsen SA  IPN.PA :
    * IPSEN PROVIDES UPDATE ON CONTACT-02 PHASE III TRIAL IN
METASTATIC CASTRATION-RESISTANT PROSTATE CANCER FOLLOWING FINAL
OVERALL SURVIVAL ANALYSIS
    * IPSEN - TRIAL DEMONSTRATED A POSITIVE TREND TOWARDS
IMPROVEMENT
FOR ONE OF PRIMARY ENDPOINTS, BUT DID NOT MEET STATISTICAL
SIGNIFICANCE
    * IPSEN SA - WILL NOT PURSUE REGULATORY SUBMISSIONS FOR
COMBINATION REGIMEN IN COUNTRIES WHERE WE HAVE COMMERCIALIZATION
RIGHTS
    * IPSEN SA - REMAIN CONFIDENT IN PROVEN PROFILE OF CABOMETYX
AS A
MONOTHERAPY AND IN COMBINATION WITH IMMUNOTHERAPY

Source text for Eikon:  ID:nGNE3sWgpq 
Further company coverage:  IPN.PA 

 ((Reuters.Briefs@thomsonreuters.com;))